Inhibrx Biosciences, Inc. Common Stock (INBX)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Inhibrx Biosciences, Inc. Common Stock (INBX) is listed on Nasdaq, where it has traded since May 28, 2024.
- Listed On
- Nasdaq
- Listed Since
- May 28, 2024
- Employees
- 110
- Market Cap
- $1.5B
About Inhibrx Biosciences, Inc. Common Stock
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 153 institutions reported holding INBX, with 13.4 million shares worth $1.3 billion in aggregate. The largest reported holder was Morgan Stanley, with 1.3 million shares worth $123.9 million. Of the 5 largest holders listed below, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Morgan Stanley | 1,308,051 | $124M | Added 3.56% |
| Perceptive Advisors | 1,297,763 | $123M | Reduced 10.05% |
| Sanofi | 1,157,926 | $110M | Unchanged |
| Viking Global Investors | 1,123,929 | $106M | Reduced 21.82% |
| Bank of America | 841,141 | $80M | Added 2473.63% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is INBX?
Inhibrx Biosciences, Inc. Common Stock (INBX) is listed on Nasdaq, where it has traded since May 28, 2024.
Who are the largest institutional holders of INBX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of INBX were Morgan Stanley, Perceptive Advisors and Sanofi.
How many institutions own INBX?
153 institutions reported a position in INBX for the quarter ended June 30, 2026, worth $1.3 billion in total.
Did institutions buy or sell INBX last quarter?
Of the 5 largest reported holders, 2 added shares, 2 reduced their positions and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for INBX.
Every reported institutional holder, plus insider and congressional trades in INBX, on SentiSense.